Pfizer Inc. and the Massachusetts Institute of Technology (MIT) today held the official groundbreaking of the new location of Pfizer's Cardiovascular, Metabolic and Endocrine Diseases (CVMED) and Neuroscience research units at 610 Main Street, Cambridge, MA.
In September, Pfizer announced it had entered into a 10-year lease agreement with MIT for more than 180,000 square feet. Taking part in the groundbreaking event were: Pfizer Board Member Dennis Ausiello, Physician-in-Chief, Massachusetts General Hospital; Chief Scientific Officer, Partners Healthcare; and Jackson Professor of Clinical Medicine, Harvard Medical School; Pfizer President of Worldwide Research and Development Mikael Dolsten; other members of the company’s Executive Leadership Team; MIT President Susan Hockfield; Massachusetts Governor Deval Patrick; and Cambridge Mayor David Maher.
Dr. Allen Krieger
, who is living with early-stage Alzheimer’s disease, also attended the ceremony with his wife Jeanne, along with Alzheimer's Association Massachusetts/New Hampshire chapter Vice President of Medical and Scientific Affairs, Jerry Flaherty.
In February Pfizer announced a strategic shift in research and development, to focus the company’s efforts on a smaller number of research areas where the potential for impact is greatest, including its CVMED and Neuroscience research units. As part of this shift, Pfizer announced it would substantially boost its presence in Cambridge by moving these two important research units there. This relocation makes Pfizer the second largest biopharmaceutical company in Massachusetts in terms of number of employees.
“We deliberately chose to move to Cambridge, MA, as a key part of our research and development strategy, in order to foster productive collaborations between our drug discovery experts and the outstanding scientists of Cambridge’s world-class institutions,” said Pfizer Worldwide R&D President Mikael Dolsten.
“This is a very exciting period in Pfizer research and development during a time of great change while we strengthen our innovative core with the goal of delivering the best medicines to patients,” said Dr. Dolsten.